Evidence map›Paper›PMID 37987824›Full record

ArticleArchives of gynecology and obstetrics2024

Pilot study of treatment of patients with deep infiltrative endometriosis with methotrexate carried in lipid nanoparticles.

Roberta Avila-Tavares, Luciano Gibran, Luiz Gustavo Oliveira Brito, Thauany Martins Tavoni, Manoel Orlando Gonçalves, Edmund Chada Baracat, Raul Cavalcante Maranhão, Sergio Podgaec

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanoceria as a non-steroidal anti-inflammatory drug for endometriosis theranostics.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  4. Article
  5. The Role of Nanomedicine in Benign Gynecologic Disorders.Molecules (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Roberta Avila-TavaresGynecological Endoscopy Center of the Perola Byington Hospital Reference for Women's Health, São Paulo, Brazil. robavila@unicamp.br.
Luciano GibranGynecological Endoscopy Center of the Perola Byington Hospital Reference for Women's Health, São Paulo, Brazil.
Luiz Gustavo Oliveira BritoDepartment of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Thauany Martins TavoniLipid Metabolism Laboratory, Heart Institute, University of Sao Paulo, São Paulo, Brazil.
Manoel Orlando GonçalvesAlta Medicina Diagnóstica, São Paulo, Brazil.
Edmund Chada BaracatDepartment of Obstetrics and Gynecology, Medical School Hospital, University of Sao Paulo, São Paulo, Brazil.
Raul Cavalcante MaranhãoLipid Metabolism Laboratory, Heart Institute, University of Sao Paulo, São Paulo, Brazil.
Sergio PodgaecDepartment of Obstetrics and Gynecology, Medical School Hospital, University of Sao Paulo, São Paulo, Brazil.
Hospital Pérola Byington · BRHospital Universitário da Universidade de São Paulo · BRUniversidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2014/03742-0
6 · The paper itself

Abstract

objectivePreviously, lipid nanoparticles (LDE) injected in women with endometriosis were shown to concentrate in the lesions. Here, the safety and feasibility of LDE carrying methotrexate (MTX) to treat deep infiltrating endometriosis was tested.

designProspective pilot study.

settingPerola Byington Hospital Reference for Women's Health. SUBJECTS: Eleven volunteers (aged 30-47 years, BMI 26.15 ± 6.50 kg/m

interventionThree patients were treated with LDE-MTX at single intravenous 25 mg/m

main outcome measuresClinical complaints, blood count, and biochemistry were analyzed before treatment and on days 90, 120, and 180 after LDE-MTX administration. Endometriotic lesions were evaluated by pelvic and transvaginal ultrasound (TVUS) before treatment and on days 30 and 180 after LDE-MTX administration.

resultsNo clinical complaints related with LDE-MTX treatment were reported by the patients, and no hematologic, renal, or hepatic toxicities were observed in the laboratorial exams. FSH, LH, TSH, free T4, anti-Müllerian hormone, and prolactin levels were also within normal ranges during the observation period. Scores for deep dyspareunia (p < 0.001), chronic pelvic pain (p = 0.008), and dyschezia (p = 0.025) were improved over the 180-day observation period. There was a non-significant trend for reduction of VAS scores for dysmenorrhea. Bowel lesions by TVUS were unchanged. No clear differences between the two dose levels in therapeutic responses were observed.

conclusionResults support the safety and feasibility of using LDE-MTX in women with deep infiltrating endometriosis as a novel and promising therapy for the disease. More prolonged treatment schemes should be tested in future placebo-controlled studies aiming to establish the usefulness of this novel nanomedicine approach.

Indexed as

DyspareuniaEndometriosisLiposomesNanoparticlesDysmenorrheaFemaleHumansMethotrexatePelvic PainPilot ProjectsProspective StudiesLipid NanoparticlesLiposomesMethotrexateBowel endometriosisDrug deliveryEndometriosis treatmentNanoemulsionsSolid lipid nanoparticles

Identifiers

PMID37987824
OpenAlexW4388862237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.